From: Gladys Edwards
Sent: 13 September 2007 16:40
To: Natalie Bemrose
Subject: STA Infliximab - Comments

Thank you for the opportunity to comment on the Appraisal Consultation Document on Infliximab for the treatment of adults with psoriasis.

This is our short statement.

The Psoriasis Association is disappointed to learn that the Committee is minded not to recommend infliximab for the treatment of adults with moderate to severe plaque psoriasis because this limits the availability of effective treatments for this difficult group of patients.

We feel that, when it is appropriate, patients should have access to the widest possible range of biologic therapies. Infliximab is recognised as 'an effective and rapidly acting treatment' and it is recognised that it 'could be more clinically effective than intermittent etanercept or efalizumab' both of which are already approved. Infliximab offers an alternative method of administration which some patients may prefer.

We hope that the issues raised about cost effectiveness are resolved positively and quickly.

Best wishes Gladys Edwards

Delivered via MessageLabs